blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2451842

EP2451842 - HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.03.2015
Database last updated on 08.04.2026
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Opsona Therapeutics Limited
Second Floor, Ashford House
Tara Street
Dublin 2 / IE
[2012/20]
Inventor(s)01 / DELLACASAGRANDE, Jerome
c/o Opsona Therapeutics Limited,
2nd Floor, Ashford House
Tara Street
Dublin 2 / IE
 [2014/07]
Former [2014/03]01 / DELLACASAGRANDE, Jerome
c/o Opsona Therapeutics Limited,
Room 2.13 1st Floor
Institute of Molecular Medicine
Trinity Centre for Life Sciences, St James' Hospital Dublin
Dublin 8 / IE
Former [2012/20]01 / DELLACASAGRANDE, Jerome
c/o Opsona Therapeutics Limited Room 2.13 1st Floor
Institute of Molecular Medicine
Trinity Centre for Life Sciences
St James' Hospital Dublin
Dublin 8 / IE
Representative(s)Carr, Anne Marie, et al
Murgitroyd & Company
Scotland House
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2012/20]Carr, Anne Marie, et al
Murgitroyd & Company Scotland House 165-169 Scotland Street Glasgow
Strathclyde G5 8PL / GB
Application number, filing date10728262.606.07.2010
WO2010EP59677
Priority number, dateIE2009000051406.07.2009         Original published format: IE 20090514
US20090270239P06.07.2009         Original published format: US 270239 P
[2012/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011003925
Date:13.01.2011
Language:EN
[2011/02]
Type: A1 Application with search report 
No.:EP2451842
Date:16.05.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 13.01.2011 takes the place of the publication of the European patent application.
[2012/20]
Type: B1 Patent specification 
No.:EP2451842
Date:14.05.2014
Language:EN
[2014/20]
Search report(s)International search report - published on:EP13.01.2011
ClassificationIPC:C07K16/28, A61P29/00, A61P11/00, A61K39/395, C12N15/13, C12N5/20
[2012/20]
CPC:
C07K16/2896 (EP,US); A61P11/00 (EP); A61P11/06 (EP);
A61P13/12 (EP); A61P17/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P25/00 (EP); A61P27/02 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P9/10 (EP);
A61K2039/505 (EP,US); C07K2317/21 (EP,US); C07K2317/76 (EP,US);
C07K2317/92 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/20]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:HUMANISIERTE ANTIKÖRPER GEGEN TOLL-LIKE-REZEPTOR 2 UND IHRE VERWENDUNG[2012/20]
English:HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF[2012/20]
French:ANTICORPS HUMANISÉS CONTRE LE RÉCEPTEUR TOLL 2 ET LEURS UTILISATIONS[2012/20]
Entry into regional phase16.01.2012National basic fee paid 
16.01.2012Designation fee(s) paid 
16.01.2012Examination fee paid 
Examination procedure16.01.2012Amendment by applicant (claims and/or description)
16.01.2012Examination requested  [2012/20]
19.07.2012Despatch of a communication from the examining division (Time limit: M06)
04.01.2013Reply to a communication from the examining division
26.03.2013Despatch of a communication from the examining division (Time limit: M04)
29.07.2013Reply to a communication from the examining division
18.12.2013Communication of intention to grant the patent
01.04.2014Fee for grant paid
01.04.2014Fee for publishing/printing paid
01.04.2014Receipt of the translation of the claim(s)
Divisional application(s)EP14158199.1  / EP2805973
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.07.2012
Opposition(s)17.02.2015No opposition filed within time limit [2015/17]
Fees paidRenewal fee
31.07.2012Renewal fee patent year 03
30.07.2013Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.07.2010
AL14.05.2014
AT14.05.2014
BG14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
MC14.05.2014
MK14.05.2014
MT14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
SM14.05.2014
TR14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
[2018/46]
Former [2018/30]HU06.07.2010
AT14.05.2014
BG14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
MC14.05.2014
MK14.05.2014
MT14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
SM14.05.2014
TR14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2016/33]HU06.07.2010
AT14.05.2014
BG14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
MC14.05.2014
MT14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
SM14.05.2014
TR14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2016/32]HU06.07.2010
AT14.05.2014
BG14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
MC14.05.2014
MT14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
SM14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2016/28]AT14.05.2014
BG14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
MC14.05.2014
MT14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
SM14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2016/22]AT14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
MC14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
SM14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2016/21]AT14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
MC14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2015/36]AT14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SI14.05.2014
SK14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2015/13]AT14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SK14.05.2014
LU06.07.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2015/11]AT14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
RO14.05.2014
SE14.05.2014
SK14.05.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2015/10]AT14.05.2014
CY14.05.2014
CZ14.05.2014
DK14.05.2014
EE14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
SE14.05.2014
SK14.05.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2015/08]AT14.05.2014
CY14.05.2014
DK14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
SE14.05.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2015/02]AT14.05.2014
CY14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
SE14.05.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
PT15.09.2014
Former [2014/51]AT14.05.2014
CY14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
SE14.05.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
Former [2014/50]CY14.05.2014
FI14.05.2014
HR14.05.2014
LT14.05.2014
LV14.05.2014
PL14.05.2014
SE14.05.2014
NO14.08.2014
GR15.08.2014
IS14.09.2014
Former [2014/49]CY14.05.2014
FI14.05.2014
LT14.05.2014
NO14.08.2014
IS14.09.2014
Former [2014/48]CY14.05.2014
LT14.05.2014
Former [2014/47]CY14.05.2014
Cited inby applicant  ANGAL S. ET AL., MOLECULAR IMMUNOLOGY, vol. 30, no. 1, 1993, pages 105 - 108
   PORTOLANO ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 150, 1993, pages 880 - 887
   CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
   SAWAI ET AL.: "Direct Production of the Fab Fragment Derived From the Sperm Immobilizing Antibody Using Polymerase Chain Reaction and CDNa Expression Vectors", AJRI, vol. 34, 1995, pages 26 - 34
   MULLINAX ET AL.: "Expression of a Heterodimeric Fab Antibody Protein in One Cloning Step", BIOTECHNIQUES, vol. 12, no. 6, 1992, pages 864 - 869
   BETTER ET AL.: "Escherichia coli Secretion of an Active Chimeric Antibody Fragment", SCIENCE, vol. 240, 1988, pages 1041 - 1043
   HUSTON ET AL.: "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins", METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 46 - 88
   MORIMOTO ET AL.: "Single-step purification of F(ab').sub.2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW", JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117
   CARTER ET AL.: "High level Escherichia coli expression and production of a bivalent humanized antibody fragment", BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
   DOUGALL ET AL.: "Design of pharmacologic agents based on antibody structure", TRENDS IN BIOTECHNOLOGY, vol. 12, 1994, pages 372 - 379
   SARAGOVI ET AL.: "Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Region", SCIENCE, vol. 253, 1991, pages 792 - 795
   SARAGOVI ET AL.: "Loops and Secondary Structure Mimetics: Development and Applications in Basic Science and Rational Drug Design", BIOTECHNOLOGY, vol. 10, 1992, pages 773 - 778
   WILLIAMS ET AL.: "Design of Bioactive Peptides Based on Antibody Hypervariable Region Structures", J.BIOL. CHEM., vol. 266, 1991, pages 5182 - 5160
   KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.